PMID- 23894157
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20201209
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 10
DP  - 2013 Oct
TI  - Elevated sclerostin levels are associated with vertebral fractures in patients 
      with type 2 diabetes mellitus.
PG  - 4030-7
LID - 10.1210/jc.2013-2143 [doi]
AB  - CONTEXT: Patients with type 2 diabetes mellitus (T2DM) patients are at increased 
      risk of vertebral fractures (VFs) compared with non-T2DM individuals, because of 
      poor bone quality. Recent studies in nondiabetic subjects have shown that 
      elevated sclerostin levels are associated with VFs independent of bone mineral 
      density (BMD). OBJECTIVE: We aimed to investigate the association between 
      sclerostin levels and VFs in T2DM. RESEARCH DESIGN AND METHODS: We conducted a 
      cross-sectional observational study in 146 postmenopausal women and 175 men over 
      50 years old. Sclerostin levels were compared in the patients with and without 
      VFs confirmed by spinal radiographs. RESULTS: Sclerostin levels were 
      significantly higher in men than in women (P < .01). Stepwise forward multiple 
      regression analyses demonstrated that spine BMD was the strongest and independent 
      positive determinant for sclerostin in both genders. When the participants were 
      divided into 2 subgroups by the T score of spine BMD to eliminate the influence 
      of BMD on sclerostin values, elevated sclerostin levels were associated with an 
      increased risk of VFs in the male patients with BMD T scores >/=-1 (odds ratio = 
      1.85, 95% confidence interval = 1.12-3.07) and female with T scores <-1 (odds 
      ratio = 3.23, 95% confidence interval = 1.42-7.34) after adjusting for multiple 
      variables including BMD and bone metabolic markers. CONCLUSIONS: Elevated 
      sclerostin levels were associated with an increased risk of VFs in T2DM patients 
      independently of BMD and bone turnover in both genders, suggesting that 
      sclerostin levels may reflect bone fragility attributed to the deterioration of 
      bone quality under the gender-specific range of BMD T scores.
FAU - Yamamoto, Masahiro
AU  - Yamamoto M
AD  - MD, PhD, Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, 
      Enya-cho, Izumo, Shimane 693-8501, Japan. masa-ya@med.shimae-u.ac.jp.
FAU - Yamauchi, Mika
AU  - Yamauchi M
FAU - Sugimoto, Toshitsugu
AU  - Sugimoto T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130726
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Genetic Markers)
RN  - 0 (SOST protein, human)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Density/*physiology
MH  - Bone Morphogenetic Proteins/*blood
MH  - Bone Remodeling/*physiology
MH  - Diabetes Mellitus, Type 2/*blood/complications/physiopathology
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk
MH  - Spinal Fractures/*blood/complications/physiopathology
EDAT- 2013/07/31 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/07/30 06:00
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - jc.2013-2143 [pii]
AID - 10.1210/jc.2013-2143 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Oct;98(10):4030-7. doi: 10.1210/jc.2013-2143. Epub 
      2013 Jul 26.